All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: University of Ulm
A PHASE3 clinical study on Acute Myeloid Leukemia, this trial is completed. The trial is conducted by University of Ulm and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Ulm
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augsburg, Germany , Bonn, Germany , Bremen, Germany , Essen, Germany , Frankfurt, Germany , Giessen, Germany , Goch, Germany , Göttingen, Germany , Hamburg, Germany , Hanau, Germany and 17 more locations